www.washingtonpost.com
Open in
urlscan Pro
23.192.7.250
Public Scan
URL:
https://www.washingtonpost.com/business/2023/12/26/ketamine-fda-matthew-perry/
Submission: On December 31 via manual from US — Scanned from US
Submission: On December 31 via manual from US — Scanned from US
Form analysis 1 forms found in the DOM
<form class="w-100 left" id="registration-form" data-qa="regwall-registration-form-container">
<div>
<div class="wpds-c-giPdwp wpds-c-giPdwp-iPJLV-css">
<div class="wpds-c-iQOSPq"><span role="label" id="radix-0" class="wpds-c-hdyOns wpds-c-iJWmNK">Enter email address</span><input id="registration-email-id" type="text" aria-invalid="false" name="registration-email"
data-qa="regwall-registration-form-email-input" data-private="true" class="wpds-c-djFMBQ wpds-c-djFMBQ-iPJLV-css" value="" aria-labelledby="radix-0"></div>
</div>
</div>
<div class="dn">
<div class="db mt-xs mb-xs "><span role="label" id="radix-1" class="wpds-c-hdyOns"><span class="db font-xxxs gray-darker pt-xxs pb-xxs gray-dark" style="padding-top: 1px;"><span>By selecting "Start reading," you agree to The Washington Post's
<a target="_blank" style="color:inherit;" class="underline" href="https://www.washingtonpost.com/information/2022/01/01/terms-of-service/">Terms of Service</a> and
<a target="_blank" style="color:inherit;" class="underline" href="https://www.washingtonpost.com/privacy-policy/">Privacy Policy</a>.</span></span></span></div>
</div>
<div id="subs-turnstile-hook" class="center dn"></div><button data-qa="regwall-registration-form-cta-button" type="submit"
class="wpds-c-kSOqLF wpds-c-kSOqLF-kXPmWT-variant-cta wpds-c-kSOqLF-eHdizY-density-default wpds-c-kSOqLF-ejCoEP-icon-left wpds-c-kSOqLF-ikFyhzm-css w-100 mt-sm"><span>Start reading</span></button>
</form>Text Content
Accessibility statementSkip to main content Democracy Dies in Darkness SubscribeSign in Close The Washington PostDemocracy Dies in Darkness Business FDA WARNING AND MATTHEW PERRY’S DEATH DARKEN KETAMINE’S GLOW By Daniel Gilbert December 26, 2023 at 6:00 a.m. EST A makeshift memorial for actor Matthew Perry, co-star of the 1990s television sitcom “Friends,” on Bedford Street in Manhattan on Oct. 30. (Mike Segar/Reuters) Listen 6 min Share Comment on this storyComment Add to your saved stories Save Federal health authorities are intensifying their scrutiny of the drug ketamine for treating mental health disorders, as the mind-altering compound grows in popularity despite the lack of regulatory approval for such use. Get a curated selection of 10 of our best stories in your inbox every weekend.ArrowRight The Food and Drug Administration warned in October about the risks of using pharmacy-made ketamine at home, citing the case of one patient whose breathing slowed to a dangerous level after taking a large dose outside of a health-care facility. Then the autopsy of actor Matthew Perry, released Dec. 15, concluded a high dose of ketamine led to his death in October — an event that, while rare, drove home the dark side of the anesthetic that can also be abused recreationally. These knocks come as the Drug Enforcement Administration continues to craft a rule that would set new limits on how health-care professionals can use telemedicine to prescribe tightly regulated drugs like ketamine. Advertisement Story continues below advertisement Ketamine has been used for anesthesia in hospitals for decades and illicitly as a club drug. In more recent years, it has shown promise as a salve for depression when conventional antidepressants have failed. The FDA approved a derivative of ketamine, the nasal spray Spravato, in 2019. But the strict rules governing the use of Spravato have led many people to seek other ways of getting the drug that are legal but not FDA-approved. Clinics have sprung up to provide infusions, while some providers prescribe a tablet that can be taken at home. The rapid expansion of ketamine out of health-care settings and into patients’ homes has heightened a debate among ketamine providers who see the drug as a critical tool for combating mental illness but disagree over how it should be used. Story continues below advertisement “This is a wake-up call for ketamine practitioners and the wider medical community to put clear and unified guardrails in place guided by real-world data and medicine,” the nonprofit American Society of Ketamine Physicians, Psychotherapists, and Practitioners said after ketamine was implicated in Perry’s death. The group pledged to create guidelines for using ketamine at home. Advertisement Many practitioners consider ketamine to be safe, with less potential for abuse than opioids. The FDA, however, hasn’t established dosing guidelines for ketamine when used for a psychiatric condition, and the agency flags safety concerns that include abuse, increases in blood pressure and bladder problems. Adding to the risk, the FDA says, is using the drug at home without a health-care provider present. Despite such alarms, there is considerable excitement about the prospects for ketamine and other drugs with psychedelic properties to treat mental health disorders. Barely two weeks after the FDA’s warning, Beckley Waves, a venture company focused on psychedelics, bought telehealth ketamine firm Nue Life for terms that weren’t disclosed. Nue Life had been valued at $103 million as of 2022, according to data provider PitchBook. Mindbloom, a rival firm, had an estimated value of $230 million as of 2021, according to the service. Story continues below advertisement Nue Life has provided at-home ketamine therapy to more than 10,000 patients across 23 states, according to the deal announcement. Daniel Love, Beckley Waves co-founder, said “through Nue Life, we can provide affordable access to safe and legal ketamine therapy,” adding that the firm takes the risks seriously and is committed to strengthening safety protocols. This doctor prescribes ketamine to thousands online. It’s all legal. One major divide among ketamine practitioners is over how and where patients receive treatment. One camp insists the drug is safest and most effective when used in the presence of a trained therapist, while others argue that allowing patients to use it at home can provide more affordable relief from depression, anxiety and post-traumatic stress disorder. Advertisement Each approach has trade-offs. A trained therapist on-site can help a patient navigate the drug’s mind-altering effects and ensure physical safety, but that can be expensive. Signing up for a virtual service can be more accessible for some, though it doesn’t come with the same level of support as an in-person experience. Story continues below advertisement Raquel Bennett, a ketamine specialist and founder of the Kriya Institute, belongs to the former camp, seeing ketamine as a tool of self-discovery. “The goal of ethical ketamine treatment is not to have clients be dependent on ketamine forever,” she said, adding that if prescribers don’t help patients learn new emotional skills, “they may be contributing to creating ketamine addiction.” Share this articleShare A spokesperson for Mindbloom said it “has helped thousands of people overcome depression and anxiety,” and that its protocols “include extensive safeguards to ensure that treatment is effective and safe.” Advertisement The debate over using ketamine at home intensified during the pandemic, as Mindbloom, Nue Life and other start-ups capitalized on a federal waiver of a requirement that prescribers evaluate patients in person before treating them with DEA-regulated drugs. This meant that doctors could prescribe ketamine to patients from their computers, often treating people in multiple states. Story continues below advertisement In March, the DEA proposed a rule to govern how health-care professionals use telehealth to prescribe controlled substances — drugs considered to have varying degrees of potential for abuse. For drugs in ketamine’s classification, a doctor could prescribe a 30-day supply through a telehealth visit but a patient would need to be evaluated in person after that for the treatment to continue. That prompted an avalanche of pushback from patients and providers who’ve come to rely on telehealth for controlled medications ranging from Adderall to benzodiazepines. Many said ketamine has been lifesaving for them. The DEA received more than 38,000 comments on its proposed telemedicine rule and a related rule for buprenorphine. Advertisement “We believe that is among the highest number of comments we have gotten in DEA’s history,” Anne Milgram, the agency’s administrator, said at a listening session in September. Story continues below advertisement Not all of those in favor of expanded access to telehealth think that ketamine should be a part of it. At the listening session in September, Georgia Gaveras, chief medical officer of Talkiatry, proposed that ketamine be excluded from the telehealth rule, pointing out that patients using Spravato have to be monitored by a health-care professional. “We also believe that the at-home prescribing of a substance that does have huge promise for depression also has very significant diversion risks, and we believe that it should be regulated further,” she said, according to an event transcript. Some pharmaceutical firms are betting they can improve on the generic ketamine that is prescribed off-label today. Advertisement Story continues below advertisement Adam Kaplin witnessed the power of ketamine while overseeing clinical trials that led to the approval of Spravato, but also saw the inconvenience and cost that comes with the FDA-required monitoring. Events like Perry’s death, he said, show “it is a very potentially dangerous practice to give patients access to this at home.” Kaplin, now chief scientific officer of Mira Pharmaceuticals, is aiming to develop a derivative of ketamine with fewer side effects. The goal, he said, is to create a drug that even the FDA will endorse as safe for patients to take at home. Share 527 Comments Loading... Subscribe to comment and get the full experience. Choose your plan → Advertisement TOP STORIES Visual stories News explained in charts, maps, photography and videos Book Tour: Celeste Ng shows us her personal library A year photographing the war in Ukraine Analysis|Take the Department of Data New Year’s Quiz Refresh Try a different topic Sign in or create a free account to save your preferences Advertisement Advertisement Company About The Post Newsroom Policies & Standards Diversity & Inclusion Careers Media & Community Relations WP Creative Group Accessibility Statement Sitemap Get The Post Become a Subscriber Gift Subscriptions Mobile & Apps Newsletters & Alerts Washington Post Live Reprints & Permissions Post Store Books & E-Books Print Archives (Subscribers Only) Today’s Paper Public Notices Coupons Contact Us Contact the Newsroom Contact Customer Care Contact the Opinions Team Advertise Licensing & Syndication Request a Correction Send a News Tip Report a Vulnerability Terms of Use Digital Products Terms of Sale Print Products Terms of Sale Terms of Service Privacy Policy Cookie Settings Submissions & Discussion Policy RSS Terms of Service Ad Choices washingtonpost.com © 1996-2023 The Washington Post * washingtonpost.com * © 1996-2023 The Washington Post * About The Post * Contact the Newsroom * Contact Customer Care * Request a Correction * Send a News Tip * Report a Vulnerability * Download the Washington Post App * Policies & Standards * Terms of Service * Privacy Policy * Cookie Settings * Print Products Terms of Sale * Digital Products Terms of Sale * Submissions & Discussion Policy * RSS Terms of Service * Ad Choices * Coupons 5.8.2 Already have an account? Sign in -------------------------------------------------------------------------------- TWO WAYS TO READ THIS ARTICLE: Create an account or sign in Free * Access this article Enter email address By selecting "Start reading," you agree to The Washington Post's Terms of Service and Privacy Policy. Start reading BEST VALUE Subscribe 50¢every week for the first year billed as $2 every 4 weeks * Unlimited access to all articles * Save stories to read later Subscribe